Knight Therapeutics Inc. (OTC:KHTRF) reported a challenging quarter with an EPS of -$0.02, missing estimates.Despite the revenue increase, the gross margin decreased to 46%, and the company's valuation ratios such as P/E and P/S suggest a premium valuation.Knight Therapeutics Inc. (OTC:KHTRF), a specialty pharmaceutical company operating across the Americas, focuses on acquiring, licensing, and marketing pharmaceutical products. Competing with other pharmaceutical firms in the region, it strives to expand i ...